research use only
Cat.No.S8740
| Related Targets | HDAC JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK |
|---|---|
| Other p300/CBP Inhibitors | Inobrodib (CCS-1477) Curcumin SGC-CBP30 Anacardic Acid CPI-637 E7386 GNE-049 Histone Acetyltransferase Inhibitor II TTK21 I-CBP112 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| MOLT3 | Function assay | 5 μM | 48 h | decreased NOTCH3 expression levels | 31001470 | |
| WM2664 | Function assay | H3K27ac IC50=0.6 μM | 30266801 | |||
| SKMEL5 | Function assay | H3K27ac IC50=0.9 μM | 30266801 | |||
| A375 | Function assay | H3K27ac IC50=1.0 μM | 30266801 | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 100 mg/mL
(186.4 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 536.48 | Formula | C25H24F4N4O5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1889279-16-6 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(C(F)(F)F)N(CC1=CC=C(C=C1)F)C(=O)CN2C(=O)C3(CCC4=C3C=CC(=C4)NC(=O)NC)OC2=O | ||
| Targets/IC50/Ki |
p300 HAT
0.06 μM
|
|---|---|
| In vitro |
A-485 is acetyl-CoA competitive p300/CBP catalytic inhibitor. This compound selectively inhibited proliferation across lineage-specific tumor types, including several hematological malignancies and androgen receptor-positive prostate cancer. It inhibited the androgen receptor transcriptional program in both androgen sensitive and castrate resistant prostate cancer. This compound inhibited the activity of the p300-BHC (bromodomain-HAT-C/H3) domain (IC50 = 9.8 nM) as well as CBP-BHC (IC50 = 2.6 nM). It is assayed against other HAT family members and does not inhibit the activity of PCAF, HAT1, MYST3, MYST4, TIP60 and GCN5L2 at 10 µM and is selective over BET bromodomain proteins and >150 non-epigenetic targets. The compound only displayed substantial binding (>90%) to dopamine and serotonin transporters at 10 µM along with modest inhibition of Plk3 (IC50=2.7 µM). As it does not achieve significant brain exposure, it is unlikely to modulate these transporters in vivo. This chemical is selective for p300/CBP over other HATs and histone methyltransferases (HMTs) in cells. It only inhibits H3K27Ac and H3K18Ac. This compound selectively inhibits hematological and prostate cancer cell proliferation and that inhibition of p300/CBP-mediated global histone acetylation does not necessarily translate to an anti-proliferative phenotype. It is primarily metabolized by CYP3A4 in vitro. This chemical also exhibits modest inhibition of CYP2C8 (IC50=0.99 μM) and CYP2C9 (IC50=1.65 μM). There was no activity toward hERG (>30 μM). |
| In vivo |
A-485 displays favorable ADME properties and PK profile. This compound inhibits tumor growth in a castration resistant xenograft model. Treatment of this chemical in LuCaP-77 CR tumor bearing mice tumor induces a decrease in tumor c-Myc protein levels and moderate body weight loss. |
References |
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | H3K9Ac / H3K18Ac / H3K27Ac p27 / FL PARP / C PARP / c-Myc |
|
28953875 |
| Growth inhibition assay | Cell viability |
|
31001470 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.